Missed GME or NVDA? Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
GYRE Stock Forecast 2025-2026
$10.39
Current Price
$963.82M
Market Cap
Buy 1
Hold 0
Sell 0
Wall St Analyst Ratings
Distance to GYRE Price Targets
+92.5%
To High Target of $20.00
+92.5%
To Median Target of $20.00
+92.5%
To Low Target of $20.00
GYRE Price Momentum
+9.0%
1 Week Change
+30.9%
1 Month Change
-32.0%
1 Year Change
-14.1%
Year-to-Date Change
-45.3%
From 52W High of $19.00
+70.0%
From 52W Low of $6.11
📉 MARKET SELLOFF ALERT
10 Quality Stocks Worth Considering Now
Researching Gyre Therapeutics (GYRE) after the drop? Our ex-Goldman Sachs analyst reveals if it made our list of 10 oversold quality stocks with strong growth potential.
Get our FREE market selloff report + exclusive analysis on GYRE and similar high-potential opportunities.
Latest GYRE Stock Price Targets & Analyst Predictions
Wall Street analysts covering GYRE have a bullish consensus with a median price target of $20.00 (ranging from $20.00 to $20.00). The overall analyst rating is Strong Buy (10.0/10). Currently trading at $10.39, the median forecast implies a 92.5% upside. This outlook is supported by 1 Buy, 0 Hold, and 0 Sell ratings.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
GYRE Analyst Ratings
1
Buy
0
Hold
0
Sell
GYRE Price Target Range
Low
$20.00
Average
$20.00
High
$20.00
Current: $10.39
Latest GYRE Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for GYRE.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|
Gyre Therapeutics Inc. (GYRE) Competitors
The following stocks are similar to Gyre Therapeutics based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Gyre Therapeutics Inc. (GYRE) Financial Data
Gyre Therapeutics Inc. has a market capitalization of $963.82M with a P/E ratio of 547.0x. The company generates $100.64M in trailing twelve-month revenue with a 7.2% profit margin.
Revenue growth is -18.8% quarter-over-quarter, while maintaining an operating margin of +10.3% and return on equity of +12.1%.
Valuation Metrics
Market Cap
$963.82M
Enterprise Value
$923.24M
P/E Ratio
547.0x
PEG Ratio
23.8x
Price/Sales
9.6x
Growth & Margins
Revenue Growth (YoY)
-18.8%
Gross Margin
+95.9%
Operating Margin
+10.3%
Net Margin
+7.2%
EPS Growth
-64.2%
Financial Health
Cash/Price Ratio
+3.3%
Current Ratio
3.6x
Debt/Equity
1.5x
ROE
+12.1%
ROA
+5.2%
💰 DON'T MISS THIS OPPORTUNITY
Get All 10 Quality Stocks For This Market Selloff
Still researching investments after the market drop? Our ex-Goldman Sachs analyst has already identified the 10 highest-quality oversold stocks with strong fundamentals and upside potential.
Why spend hours researching when we've already done the work? Get instant access to our complete market selloff analysis.
Gyre Therapeutics Inc. (GYRE) Business Model
About Gyre Therapeutics Inc.
What They Do
Develops innovative therapies for unmet medical needs.
Business Model
Gyre Therapeutics generates revenue through its focused research and development of novel therapies, particularly in oncology, neurology, and rare genetic disorders. The company employs a robust pipeline strategy that combines in-house R&D with strategic collaborations, allowing it to accelerate drug development and facilitate clinical trials, thus driving potential future sales from successful product launches.
Additional Information
By partnering with academic institutions and pharmaceutical companies, Gyre Therapeutics enhances its scientific capabilities and expands its therapeutic portfolio, positioning itself as a key player in advancing medical science and transforming patient care with new bio-pharmaceutical products.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
579
CEO
Dr. Han Ying Ph.D.
Country
United States
IPO Year
2006
Website
www.gyretx.comGyre Therapeutics Inc. (GYRE) Latest News & Analysis
Latest News
Gyre Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update
6 days ago
Quick Summary
Gyre Therapeutics reported Q1 2025 revenue of $22.1 million and EPS of $0.03. They achieved database lock for a Phase 3 trial and received IND approval for a new cancer treatment. $51.3 million in cash on hand.
Why It Matters
Gyre Therapeutics' revenue growth, trial progress, and new drug approvals indicate potential for future earnings and market expansion, key factors for investment valuation and strategic positioning.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Gyre Therapeutics (Nasdaq: GYRE) received approval from China's NMPA for a clinical trial of pirfenidone to treat radiation-induced lung injury, expanding its oncology-related applications.
Why It Matters
Approval of Gyre's clinical trial in China for a new indication of pirfenidone could expand its market potential, enhancing revenue prospects and boosting investor confidence.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Gyre Therapeutics (Nasdaq: GYRE) announced the publication of a Phase 3 trial protocol for hydronidone, targeting liver fibrosis in chronic hepatitis B patients, in the Journal of Clinical and Translational Hepatology.
Why It Matters
Gyre Therapeutics' Phase 3 trial protocol publication signals potential advancements in liver fibrosis treatment, impacting stock value and investor confidence in biotech innovation and market potential.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Gyre Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
1 month ago
Quick Summary
Gyre Therapeutics expects pivotal Phase 3 trial data in Q2 2025 and revenue guidance of $118-$128 million for full year 2025. Launch of generic nintedanib and avatrombopag also anticipated in 2025.
Why It Matters
Gyre Therapeutics anticipates significant revenue growth and key trial results in 2025, indicating potential for stock price appreciation and market expansion, crucial for investor confidence.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Gyre Therapeutics Reports Third Quarter 2024 and Year-To-Date Financial Results and Provides Business Update
6 months ago
Quick Summary
Gyre Therapeutics reported Q3 2024 results with $15.9M in cash. A Phase 3 trial for F351 in liver fibrosis is complete, with data due in Q1 2025. U.S. Phase 2 trial starts in 2025; drug launches expected in 2025.
Why It Matters
Gyre Therapeutics' Phase 3 trial completion and upcoming drug launches signal potential revenue growth. Their cash position will impact funding for upcoming trials and operations.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Gyre Therapeutics has completed patient enrollment in a Phase 3 trial for F351 in Chronic Hepatitis B-related liver fibrosis. Topline results are expected by Q1 2025.
Why It Matters
The completion of the Phase 3 trial for F351 in China signals potential FDA approval, impacting Gyre's market potential and stock performance. Topline data due early 2025 could influence investor sentiment.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Frequently Asked Questions About GYRE Stock
What is Gyre Therapeutics Inc.'s (GYRE) stock forecast for 2025?
Based on our analysis of 0 Wall Street analysts, Gyre Therapeutics Inc. (GYRE) has a median price target of $20.00. The highest price target is $20.00 and the lowest is $20.00.
Is GYRE stock a good investment in 2025?
According to current analyst ratings, GYRE has 1 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $10.39. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for GYRE stock?
Wall Street analysts predict GYRE stock could reach $20.00 in the next 12 months. This represents a 92.5% increase from the current price of $10.39. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Gyre Therapeutics Inc.'s business model?
Gyre Therapeutics generates revenue through its focused research and development of novel therapies, particularly in oncology, neurology, and rare genetic disorders. The company employs a robust pipeline strategy that combines in-house R&D with strategic collaborations, allowing it to accelerate drug development and facilitate clinical trials, thus driving potential future sales from successful product launches.
What is the highest forecasted price for GYRE Gyre Therapeutics Inc.?
The highest price target for GYRE is $20.00 from at , which represents a 92.5% increase from the current price of $10.39.
What is the lowest forecasted price for GYRE Gyre Therapeutics Inc.?
The lowest price target for GYRE is $20.00 from at , which represents a 92.5% increase from the current price of $10.39.
What is the overall GYRE consensus from analysts for Gyre Therapeutics Inc.?
The overall analyst consensus for GYRE is bullish. Out of 0 Wall Street analysts, 1 rate it as Buy, 0 as Hold, and 0 as Sell, with a median price target of $20.00.
How accurate are GYRE stock price projections?
Stock price projections, including those for Gyre Therapeutics Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: May 16, 2025 12:40 AM UTC